CN111788207A - 二噁烷并喹啉类化合物及其制备方法与应用 - Google Patents

二噁烷并喹啉类化合物及其制备方法与应用 Download PDF

Info

Publication number
CN111788207A
CN111788207A CN201980012397.7A CN201980012397A CN111788207A CN 111788207 A CN111788207 A CN 111788207A CN 201980012397 A CN201980012397 A CN 201980012397A CN 111788207 A CN111788207 A CN 111788207A
Authority
CN
China
Prior art keywords
alkyl
substituted
group
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980012397.7A
Other languages
English (en)
Other versions
CN111788207B (zh
Inventor
张强
于善楠
王中祥
冯守业
孙月明
刘彦生
张宏波
杨磊夫
杨海龙
周利凯
郑南桥
胡晨明
徐占强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Scitech MQ Pharmaceuticals Ltd
Original Assignee
Beijing Scitech MQ Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076233 external-priority patent/WO2018153293A1/zh
Application filed by Beijing Scitech MQ Pharmaceuticals Ltd filed Critical Beijing Scitech MQ Pharmaceuticals Ltd
Priority claimed from PCT/CN2019/073260 external-priority patent/WO2019154133A1/zh
Publication of CN111788207A publication Critical patent/CN111788207A/zh
Application granted granted Critical
Publication of CN111788207B publication Critical patent/CN111788207B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

本发明公开了具有式(I)的二噁烷并喹啉类化合物或其可药用盐。本发明还提供了一种式(I)所述化合物及其可药用盐的制备和作为药物的应用，所述药物作为酪氨酸激酶(例如VEGFR‑2和c‑MET)抑制剂用于治疗与酪氨酸激酶相关的疾病。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201980012397.7A 2017-02-27 2019-01-25 二噁烷并喹啉类化合物及其制备方法与应用 Active CN111788207B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201710107756 2017-02-27
CN201710161873.4A CN108503650B (zh) 2017-02-27 2017-03-17 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用
CNPCT/CN2018/076233 2018-02-11
PCT/CN2018/076233 WO2018153293A1 (zh) 2017-02-27 2018-02-11 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
CN201810983341.3A CN110156803A (zh) 2017-02-27 2018-08-27 二噁烷并喹啉类化合物及其制备方法与应用
CN2018109833413 2018-08-27
PCT/CN2019/073260 WO2019154133A1 (zh) 2018-02-11 2019-01-25 二噁烷并喹啉类化合物及其制备方法与应用

Publications (2)

Publication Number Publication Date
CN111788207A true CN111788207A (zh) 2020-10-16
CN111788207B CN111788207B (zh) 2021-03-23

Family

ID=63374400

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201710161873.4A Active CN108503650B (zh) 2017-02-27 2017-03-17 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用
CN201810983341.3A Pending CN110156803A (zh) 2017-02-27 2018-08-27 二噁烷并喹啉类化合物及其制备方法与应用
CN201980012397.7A Active CN111788207B (zh) 2017-02-27 2019-01-25 二噁烷并喹啉类化合物及其制备方法与应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201710161873.4A Active CN108503650B (zh) 2017-02-27 2017-03-17 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用
CN201810983341.3A Pending CN110156803A (zh) 2017-02-27 2018-08-27 二噁烷并喹啉类化合物及其制备方法与应用

Country Status (5)

Country Link
CN (3) CN108503650B (zh)
AU (1) AU2019218187B2 (zh)
DK (1) DK3750893T3 (zh)
ES (1) ES2945573T3 (zh)
SG (1) SG11202007554TA (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11731946B2 (en) 2017-10-19 2023-08-22 The General Hospital Corporation Broad spectrum antivirulence, anti-persistence compounds

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156804B (zh) * 2018-02-11 2021-01-12 北京赛特明强医药科技有限公司 一种二噁烷并喹啉类化合物及其制备方法
CN111196814B (zh) * 2018-11-19 2022-12-06 北京赛特明强医药科技有限公司 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法
CN112939995A (zh) * 2021-02-02 2021-06-11 北京工业大学 二噁烷并喹唑啉衍生物制备方法
CN114957136A (zh) * 2021-02-24 2022-08-30 南京科默生物医药有限公司 一种用作vegfr抑制剂的抗肿瘤化合物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
CN103328447A (zh) * 2010-09-12 2013-09-25 南京爱德程医药科技有限公司 作为c-Met激酶抑制剂的化合物
CN103402505A (zh) * 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性***癌和成骨性骨转移的met和vegf的双重抑制剂
CN104530063A (zh) * 2015-01-13 2015-04-22 北京达立泰制药科技有限公司 喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用
CN105541798A (zh) * 2016-02-03 2016-05-04 中国人民解放军第二军医大学 具有抗肿瘤活性的喹啉类多靶点激酶抑制剂及其制备方法
CN105837586A (zh) * 2015-12-14 2016-08-10 北京赛特明强医药科技有限公司 二噁烷并喹唑啉胺类化合物及其制备方法和作为表皮生长因子受体抑制剂的应用
WO2018153293A1 (zh) * 2017-02-27 2018-08-30 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
CN103328447A (zh) * 2010-09-12 2013-09-25 南京爱德程医药科技有限公司 作为c-Met激酶抑制剂的化合物
CN103402505A (zh) * 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性***癌和成骨性骨转移的met和vegf的双重抑制剂
CN104530063A (zh) * 2015-01-13 2015-04-22 北京达立泰制药科技有限公司 喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用
CN105837586A (zh) * 2015-12-14 2016-08-10 北京赛特明强医药科技有限公司 二噁烷并喹唑啉胺类化合物及其制备方法和作为表皮生长因子受体抑制剂的应用
CN105541798A (zh) * 2016-02-03 2016-05-04 中国人民解放军第二军医大学 具有抗肿瘤活性的喹啉类多靶点激酶抑制剂及其制备方法
WO2018153293A1 (zh) * 2017-02-27 2018-08-30 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARUN K.GHOSH 等: "《基于结构的药物及其他生物活性分子设计：工具和策略》", 31 January 2017, 科学出版社 *
J. JEAN CUI: "Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
XUEMEI QIN 等: "Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
ZHENGSHENG ZHAN 等: "Discovery of Anilinopyrimidines as Dual Inhibitors of c‑Met and VEGFR-2: Synthesis, SAR, and Cellular Activity", 《MEDICINAL CHEMISTRY LETTERS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11731946B2 (en) 2017-10-19 2023-08-22 The General Hospital Corporation Broad spectrum antivirulence, anti-persistence compounds

Also Published As

Publication number Publication date
SG11202007554TA (en) 2020-09-29
DK3750893T3 (da) 2023-05-08
CN111788207B (zh) 2021-03-23
AU2019218187A1 (en) 2020-09-10
ES2945573T3 (es) 2023-07-04
CN110156803A (zh) 2019-08-23
AU2019218187B2 (en) 2021-10-14
CN108503650B (zh) 2021-02-12
CN108503650A (zh) 2018-09-07

Similar Documents

Publication Publication Date Title
CN111788207B (zh) 二噁烷并喹啉类化合物及其制备方法与应用
CN111757885B (zh) 脲取代的芳环连二噁烷并喹啉类化合物及其制备方法与应用
WO2018153293A1 (zh) 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
CN111196814B (zh) 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
WO2013032797A2 (en) Oxetane 3,3-dicarboxamide compounds and methods of making and using same
WO2018157730A1 (zh) 脲取代的芳环连二噁烷并喹唑啉与连二噁烷并喹啉类化合物及其制备方法与应用
CN110862397A (zh) 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
CN110229171B (zh) 一种噁嗪并喹唑啉与噁嗪并喹啉类化合物及其制备方法和应用
JP7022454B2 (ja) ジオキシノキノリン系化合物、その調製方法および使用
CN110229172B (zh) 一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用
CA3090829C (en) Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
CN103509024A (zh) 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用
CN112442045B (zh) 一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用
WO2015035866A1 (zh) 新型抗肿瘤化合物、药物组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039351

Country of ref document: HK